Table 4.
Summary of the MBP-and peptide-specific T-cell clones
| TCC | MBP region | Specific peptide |
|---|---|---|
| MS39:A7* | 1–24 | 5–19 |
| MS49:D3* | 30–54 | 30–44 |
| MS49:C8* | 30–54 | 30–44 |
| MS49:A8* | 30–54 | 30–44 |
| MS49:B6* | 30–54 | 30–44 |
| MS39:D7* | 60–84 | 60–74 |
| MS43:A7* | 75–99 | 83–99 |
| MS41:B6* | 75–99 | 83–99 |
| MS41:A2* | 75–99 | 83–99 |
| MS41:C6* | 75–99 | 83–99 |
| N5:8 † | 75–99 | 83–99 |
| MS60:A2* | 105–129 | 110–124 |
| MS60:B3* | 105–129 | 110–124 |
| MS60:E1* | 120–144 | 130–144 |
| MS17:A3* | 120–144 | 130–144 |
| MS60:F7* | 135–159 | 140–154 |
| MS60:D1* | 135–159 | 140–154 |
| MS57:A1* | 135–159 | 140–149 |
| MS59:F1* | 135–159 | 140–154 |
| N5:19 † | 135–159 | 140–154 |
| MS43 A3 * | 150–170 | 156–169 |
| MS43:D2† | 150–170 | 156–169 |
A map of the specificity of the peptide regions identified in the kinetic response assay was obtained through the use of TCC generated from MS patients and healthy individuals. Most of the peptides used in screening assays were 15-mer in length. However, a few were 10-mer, and one peptide was 17-mer. The specificity of each TCC was tested at least two times.
*
TCC derived from MS patients.
†
TCC derived from healthy individuals.